Posted by Michael Wonder on 17 Oct 2024
Eplontersen approved to treat adults with rare inherited nerve disease or polyneuropathy
16 October 2024 - The MHRA has approved eplontersen (Wainzua) to treat adults with polyneuropathy associated with hereditary transthyretin amyloidosis, which is a rare progressive condition that runs in families caused by a protein called transthyretin.
The MHRA’s approval of the medicine is supported by evidence from a NEURO-TTRansform study.
